Dr. Andrew Snyder (Monash University) joins the show to discuss the current biotech landscape: rising M&A and IPO activity, ...

But what if one of them encounters significant competition soon? That's what some investors believe might happen, given ...

Significant news coverage and COVID-19 flashbacks have driven investors into biotech stocks over the past week.

Focused on immunology-based therapies for infectious diseases, this biotech company reported a notable insider sale in recent ...

An expert from Northway Biotech and Lithuania’s Minister of Economy and Innovation talk about how the country is poised to be ...

Discover how CellResearchCorp pivoted from a biotech winter to a $25 million revenue turnaround in four years by focusing on ...

After several challenging quarters, Regeneron's sales growth is rebounding. In the first quarter, the company's revenue rose ...

Krystal Biotech leverages its HSV-1 gene delivery platform, with VYJUVEK generating strong cash flow. Read why I rate KRYS ...

Krystal Biotech, Inc. reported Q1 2026 net income of US$55.93 million, with basic EPS from continuing operations rising to US$1.91, and later in May the company’s leadership participated in the BofA ...

CARVYKTI® (ciltacabtagene autoleucel; cilta-cel) net trade sales increased 62% versus first quarter of 2025 to approximately ...

Biotech stocks are gaining momentum on M&A activity, cancer drug launches and upcoming autoimmune treatment data.